Navigation Links
NIH awards grant to Banner Alzheimer's Institute for major prevention study
Date:9/18/2013

In collaboration with the National Institutes of Health (NIH), Banner Alzheimer's Institute (BAI) announces a major prevention trial to evaluate a treatment in cognitively healthy older adults at the highest known genetic risk for developing Alzheimer's disease at older ages. An NIH grant, expected to total $33.2 million, will support this research. (NIA support: AG 046150-01)

The study is part of the Alzheimer's Prevention Initiative (API), an international collaboration led by BAI to accelerate the evaluation of promising but unproven prevention therapies. It will test an anti-amyloid treatment in about 650 adults, ages 60-75, who have two copies of the apolipoprotein E (APOE4) gene, the major genetic risk factor for late-onset Alzheimer's. None of the participants will have impairments in memory or thinking at the time they enter the study.

"Once again, we are extremely grateful to the NIH for the opportunity to help accelerate the evaluation of treatments to prevent the clinical onset of Alzheimer's and find ones that work as soon as possible," said Dr. Eric M. Reiman, BAI Executive Director. "This trial will allow us to extend our work to individuals at greatest risk at older ages."

The randomized, placebo-controlled trial, which will take place at BAI and other U.S. sites, will test the treatment's ability to stave off the memory and thinking declines associated with Alzheimer's. It will also assess the treatment's effects on different brain imaging and cerebrospinal fluid measurements of the disease. The specific compound to be evaluated has not been decided.

The trial will test what is often called the amyloid hypothesis, which suggests that accumulation of the protein amyloid in the brain plays a key role in the disease's progression. Major funding from philanthropy and industry will also support the trial, and its leaders expect to provide data and biological samples to the research community after the trial's conclusion to help in the scientific fight against Alzheimer's.

Individuals in the study will learn their APOE4 status. To help them prepare for this information, BAI has convened an expert committee to develop a comprehensive genetic testing and disclosure plan and to assess the impact of this disclosure during the trial.

"Under the National Plan to Address Alzheimer's Disease, our goal is to prevent and effectively treat the disorder by 2025," said Dr. Neil Buckholtz, of the National Institute on Aging, which leads Alzheimer's research at the National Institutes of Health.

"We are delighted to support Dr. Reiman, Dr. Tariot and their team in this innovative clinical trial aimed at preventing the onset and progression of this devastating disease."

The research is intended to complement API's initial trial, which is primarily focused in Colombia and involves about 300 people from an extended family with a rare genetic mutation that typically triggers Alzheimer's symptoms around age 45. That work also is focusing on an anti-amyloid therapy and its potential in slowing or blocking the disease while preserving cognitive abilities. The investigation, including a smaller U.S. companion study, dovetails with prevention trials that have been planned or started by other research groups during the past 16 months.

"We are now looking at potential treatments to prevent both the early and late onset forms of the disease," said Dr. Pierre N. Tariot, BAI Director. "This kind of comprehensive approach could prove the tipping point in our long, arduous effort to find a way to end this devastating disease."

The new trial will draw participants mainly from the Alzheimer's Prevention Registry, an online community of people who are committed to helping in the fight against Alzheimer's. The Registry provides regular updates on the latest scientific advances, as well as information on overall brain health. To overcome one of the biggest obstacles to clinical research, the Registry supports enrollment in a variety of Alzheimer's prevention studies within members' communities.

Alzheimer's is a debilitating and incurable disease that affects more than 5.2 million Americans, with a new diagnosis every 68 seconds. Without the discovery of successful prevention therapies, the number of U.S. cases is projected to nearly triple by 2050.


'/>"/>

Contact: Kate Enos
kenos@gymr.com
202-745-5071
GYMR
Source:Eurekalert

Related medicine news :

1. T.E.N. Announces Nominees for the 2013 ISE® North America Awards
2. Tri-County Electric People Fund Awards Grant To Eagle Village
3. Parent Magic Inc's "Surviving Your Adolescents" Wins Gold Award in National Parenting Publications Awards 2013
4. Jose’s Hands to Host The World’s First Red Carpet Medical Mission Awards in Miami Beach
5. Extended-Car-Warranty.com Awards CARCHEX with the 2013 Gold Award after Conducting Reviews of Extended Auto Warranty Companies
6. Jury Awards Sacramento Woman $680,000 for Auto Accident Caused by Distracted Driving
7. USHEALTH Advisors, LLC Announces its Selection as Bronze Stevie® Award Winner in 2013 International Business Awards
8. It Works! Global Awards Kami Dempsey With "Black Diamond" Title
9. Kids II® Wins Thirteen 2013 American Inhouse Design Awards
10. ASTRO awards $34,500 in individual grants to top researchers presenting at the 2013 Annual Meeting
11. Entries Now Open for HREI Insights Awards™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... June 25, 2017 , ... June is Men’s Health Month and the ... common cancer among men in the U.S. and the third most common cause of cancer ... that one man in seven will be diagnosed with prostate cancer during his lifetime. ...
(Date:6/24/2017)... ... June 24, 2017 , ... The weather is heating ... outdoors. Home and business owners should be aware that the summer months provide more ... fact, mechanical locks and keys can be negatively affected from direct exposure to the ...
(Date:6/23/2017)... ... 23, 2017 , ... By scoring 100% for fiscal management and accountability, the ... online charity evaluator, Charity Navigator, validating ANRF's work as a top charity in America. ... Charity Navigator and earns ANRF a spot on their “ 10 Charities Worth Watching ...
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. ... has recently begun offering three new minimally invasive procedures to patients who want ... reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet ...
(Date:6/23/2017)... ... ... The Aesthetic Channel has recently highlighted Dr. Ben Talei’s unique approach to ... technique that he calls the AuraLyft Facelift. The AuraLyft does more than ... expect to look refreshed, rejuvenated, and revitalized. , Dr. Talei’s unique approach stems ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... and INDIANAPOLIS , June 9, ... living with diabetes. In a further effort to help ... affected by this condition, the International Diabetes Federation (IDF) ... ) have come together for the second phase of ... Systems programme (BRIDGES 2), reaffirming their commitment to helping ...
(Date:6/7/2017)... GAITHERSBURG, Md. , June 7, 2017  Novavax, Inc., ... the second of two Phase 2 trials of its RSV ... women of child bearing age have been published in the ... this publication have been shared in prior scientific conferences). The ... trial in April 2014. Novavax is developing the RSV F ...
(Date:6/2/2017)... LAWRENCE, Mass. , June 2, 2017  NxStage ... advancing renal care, today announced new findings demonstrating positive ... NxStage ® System One™. The data will be ... 2017, in Madrid, Spain . ... Knowledge to Improve Home Dialysis Network in ...
Breaking Medicine Technology: